SARS‑COV‑2
VACCINATION
A Development
Vaccine development sponsored by Moderna has started a phase 3 trial of ~30,000 participants.
Participants received a standard arm injection of the mRNA vaccine on Day 1 and follow up on Day 29.
Primary results demonstrated
Vaccine efficacy against COVID-19 was 94.1%
Vaccine efficacy against severe COVID-19 was 100%
196 cases of COVID-19, of which 30 cases were severe
MRNA VACCINE
mRNA for viral protein is provided to cell. mRNA unique to the Spike protein of COVID-19 is transcribed.
Effects
Only part of the protein is present therefore infection cannot occur and COVID cannot be contracted.
Transcribed portion still antigenic.
Marks of Successful Vaccine Candidates
elicit antiviral SARS-CoV-2-specific CD4+ and CD8+ T cell responses
produce neutralizing antibodies that generate immunity
coordinate a controlled adaptive immune response that will not result in the overstimulation of inflammatory cytokines.